Inside the research
TransMedics Group, Inc.
TMDX Research profile · latest available data
Price overview
$85.29
▲ +1.39 (+1.7%)
| 52w hi | $150.42 |
|---|---|
| 52w lo | $62.04 |
| Vol | 696.70K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.19
| Short | -0.21 |
|---|---|
| Medium | -0.12 |
| Long | -0.28 |
computed 2026-09-27
Key fundamentals
TransMedics Group, Inc.
Healthcare · Medical Devices
| Market cap | $2.96B |
|---|---|
| Enterprise value | $3.35B |
| Trailing P/E | 22.10x |
| Forward P/E | 37.34x |
| EV / EBITDA | 28.99x |
| P / S (ttm) | 4.41x |
| Profit margin | 22.7% |
| Return on equity | 36.3% |
| Revenue growth | +20.7% |
| Earnings growth | -55.8% |
| Debt / equity | 167.50 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.05 | |
| Sector | +0.08 | |
| Technical | -0.17 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Risk Metrics
| Beta vs SPX | 1.17 |
|---|---|
| Corr SPX | 0.30 |
| Annual vol | 63.7% |
| Annual ret | -12.0% |
| Sharpe | -0.19 |
| Max DD | -64.4% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-05-21 | Shareholder Vote, Exhibits | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-02-27 | Earnings Release, Exhibits | read |
| 2026-02-24 | Earnings Release, Exhibits | read |
| 2026-02-04 | Officer / Director Change | read |
| 2026-01-12 | Material Agreement, Other Material Event… | read |
| 2025-10-29 | Earnings Release, Exhibits | read |
| 2025-10-06 | Acquisition / Disposition | read |
| 2025-07-30 | Earnings Release, Exhibits | read |
| 2025-05-23 | Shareholder Vote | read |
| 2025-05-08 | Earnings Release, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 100.0% |
| HHI | 5,339 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Citadel Advisors | $94.13M | 1.42M |
| Millennium Management | $17.47M | 263.01K |
| State Street Corp | $13.00M | 11.94M |
| Fidelity / FMR LLC | $6.03M | 5.58M |
| AQR Capital Management | $1.86M | 27.95K |
| T. Rowe Price Group | $3.06K | 46.03K |
| Capital Research / Capital World | $1.08K | 1.00K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2019–2025 · 7 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $605.49M | +143.4% | |
| Gross profit | $262.08M | +156.3% | |
| Operating income | $108.58M | +189.6% | |
| Net income | $190.29M | — | |
| Cash from ops | $48.80M | +0.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $83.50 | $85.69 | $81.80 | $85.29 | 696.70K |
| Sep 24 | $86.09 | $86.09 | $82.53 | $83.90 | 623.70K |
| Sep 23 | $88.22 | $89.19 | $85.07 | $87.00 | 615.60K |
| Sep 22 | $88.15 | $89.80 | $86.50 | $88.07 | 750.70K |
| Sep 21 | $87.35 | $89.53 | $86.75 | $87.29 | 590.80K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →